Publication

Therapeutic oligonucleotides in the GenTerre: design, synthesis and validation in vitro and in vivo

The use of synthetic oligonucleotides in medicine is one of the revolutionary approaches for effective and selective therapy of a number of diseases. To date, 15 drugs based on synthetic miRNAs and antisense oligonucleotides have been approved in the world [1, 2]. The biotech company JSC GenTerra offers a full range of services for the design, synthesis and purification of synthetic miRNAs, antisense oligonucleotides, aptamers, guide RNAs for the inhibition of genes-potential targets for therapy in vitro and in vivo, and also specializes in the synthesis of primers, chemically modified oligonucleotides, fluorescently labeled probes used in PCR,PCR, in situ fluorescent hybridization, genotyping and other methods of molecular biology and diagnostics. The company offers magnetic sorbents for the isolation of nucleic acids of its own production, develops new enzymes for PCR and RT-PCR and kits based on them. JSC GenTerra provides services for the synthesis of oligonucleotides for applications in preclinical studies (in quantities up to several grams), including the development of bioanalytical methods (HPLC-MS and HPLC-MS/MS), additional purification methods, endotoxin testing and testing of miRNA/antisense RNAs in vitro/in vivo, as well as viability assessment, migration and apoptosis in cells. We also offer various works on cloning and assembling control samples based on lambda and MS2 phages for in vitro diagnostics. The team of JSC GenTerra is open to new cooperation and projects both in the field of molecular diagnostics and in the scientific field.